ArticleBritish journal of clinical pharmacology2011
Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal.
Article in British journal of clinical pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacokinetics of Antimicrobials and Carriage of Antimicrobial Resistance Amongst Hospitalised Children With Severe Acute Malnutrition
Point-of-care Monitoring of Antibiotic Concentration in Blood With UV-VIS Absorption Spectroscopy
Who cites it
43 citing papers in PubMed, 77 citations in OpenAlex.
- Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions?The Journal of antimicrobial chemotherapy · 2023Trial
- High-Dose Ceftriaxone for Bacterial Meningitis and Optimization of Administration Scheme Based on Nomogram.Antimicrobial agents and chemotherapy · 2019Trial
- Dosing of Ceftriaxone and Metronidazole for Children With Severe Acute Malnutrition.Clinical pharmacology and therapeutics · 2018Trial
- Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.Journal of clinical pharmacology · 2014Trial
- High-dose ceftriaxone: Pharmacokinetic and pharmacodynamic insights in hospitalized patients with suspected sepsis in Thailand.British journal of clinical pharmacology · 2026Article
- Can Model-Informed Precision Dosing of Beta-Lactams in Critical Care Improve Clinical Outcomes?Chemotherapy · 2026Review
- Ceftriaxone 1 g versus 2 g per day, for the treatment of community-acquired pneumonia: a retrospective cohort study-comment.Internal and emergency medicine · 2025Article
- Pathogen spectrum, clinical traits and exploration of mortality outcome-improving medication regimens in coinfection patients with severe fever with thrombocytopenia syndrome: a multicenter cohort study.Frontiers in cellular and infection microbiology · 2025Article
- Rationale and Logistics of Continuous Infusion Cephalosporin Antibiotics.Pharmacy (Basel, Switzerland) · 2024Review
- Impact of hypoalbuminemia on clinical outcomes among patients with obesity treated with ceftriaxone.Antimicrobial agents and chemotherapy · 2024Article
- Endotoxin-Induced Sepsis on Ceftriaxone-Treated Rats' Ventilatory Mechanics and Pharmacokinetics.Antibiotics (Basel, Switzerland) · 2024Article
- Evaluation of ceftriaxone pharmacokinetics in hospitalized Egyptian pediatric patients.European journal of pediatrics · 2023Article
- Impact of Hypoalbuminemia on Ceftriaxone Treatment Failure in Patients With Enterobacterales Bacteremia: A Propensity-Matched, Retrospective Cohort Study.Open forum infectious diseases · 2023Article
- Pharmacokinetic/Pharmacodynamic Index Linked toAntimicrobial agents and chemotherapy · 2023Article
- Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients.Antimicrobial agents and chemotherapy · 2022Article
- Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study).Clinical pharmacokinetics · 2022Article
- Population Pharmacokinetic Modeling of Total and Free Ceftriaxone in Critically Ill Children and Young Adults and Monte Carlo Simulations Support Twice Daily Dosing for Target Attainment.Antimicrobial agents and chemotherapy · 2022Article
- β-lactam precision dosing in critically ill children: Current state and knowledge gaps.Frontiers in pharmacology · 2022Review
- Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.Clinical pharmacokinetics · 2021Observational
- Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration.European journal of clinical pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate the population pharmacokinetics of ceftriaxone in critically ill patients suffering from sepsis, severe sepsis or septic shock.
methodsBlood samples were collected at preselected times in 54 adult patients suffering from sepsis, severe sepsis or septic shock in order to determine ceftriaxone concentrations using high-performance liquid chromatography-ultraviolet detection. The pharmacokinetics of ceftriaxone were assessed on two separate occasions for each patient: on the second day of ceftriaxone therapy and 48 h after catecholamine withdrawal in patients with septic shock, or on the fifth day in patients with sepsis. The population pharmacokinetics of ceftriaxone were studied using nonlinear mixed effects modelling.
resultsThe population estimates (interindividual variability; coefficient of variation) for ceftriaxone pharmacokinetics were: a clearance of 0.88 l h(-1) (49%), a mean half-life of 9.6 h (range 0.83-28.6 h) and a total volume of distribution of 19.5 l (range 6.48-35.2 l). The total volume of distribution was higher than that generally found in healthy individuals and increased with the severity of sepsis. However, the only covariate influencing the ceftriaxone pharmacokinetics was creatinine clearance. Dosage simulations showed that the risk of ceftriaxone concentrations dropping below the minimum inhibitory concentration threshold was low.
conclusionsDespite the wide interpatient variability of ceftriaxone pharmacokinetic parameters, our results revealed that increasing the ceftriaxone dosage when treating critically ill patients is unnecessary. The risk of ceftriaxone concentrations dropping below the minimum inhibitory concentration threshold is limited to patients with high glomerular filtration rates or infections with high minimum inhibitory concentration pathogens (>1 mg l(-1)).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.